A detailed history of Washington Trust CO transactions in Exelixis, Inc. stock. As of the latest transaction made, Washington Trust CO holds 2,800 shares of EXEL stock, worth $62,019. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,800
Previous 2,800 -0.0%
Holding current value
$62,019
Previous $67,000 1.49%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 10, 2023

BUY
$16.3 - $19.41 $45,591 - $54,289
2,797 Added 93233.33%
2,800 $54,000
Q1 2023

May 04, 2023

SELL
$16.3 - $19.41 $45,591 - $54,289
-2,797 Reduced 99.89%
3 $54,000
Q1 2020

May 07, 2020

BUY
$14.46 - $21.8 $40,488 - $61,040
2,800 New
2,800 $48,000
Q3 2018

Nov 13, 2018

SELL
$15.87 - $22.4 $44,436 - $62,719
-2,800 Closed
0 $0
Q2 2018

Aug 10, 2018

BUY
$18.56 - $22.45 $51,968 - $62,860
2,800 New
2,800 $60,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $7.13B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Washington Trust CO Portfolio

Follow Washington Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Washington Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Washington Trust CO with notifications on news.